Constantly Strategical Planning High-Growth Sectors, Grand Pharma’s 2022 Interim Results Continue to Grow
- Written by Viw Magazine
HONG KONG SAR - Media OutReach - 11 August 2022- Grand Pharma (0512.HK, the "Company") announced its 2022 interim results recently. During the first half of 2022 (the "Period"), the Company recorded revenue of approximately HKD 5.21 billion, representing an increase of 14.1% YoY; net profit attributable to owners of the company of HKD 1.09 billion (excluding the changes in investment in Telix), representing an increase of 20.1% YoY.